Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study
Idanna Innocenti, Gianluigi Reda, Andrea Visentin, Marta Coscia, Marina Motta, Roberta Murru, Riccardo Moia, Massimo Gentile, Elsa Pennese, Francesca Maria Quaglia, Francesco Albano, Ramona Cassin, Marina Deodato, Claudia Ielo, Anna Maria Frustaci, Alfonso Piciocchi, Arianna Rughini, Valentina Arena, Daniela Di Sevo, Annamaria Tomasso, Francesco Autore, Giovanni Del Poeta, Lydia Scarfò, Francesca Romana Mauro, Alessandra Tedeschi, Livio Trentin, Maurizio Pompili, Robin Foà, Paolo Ghia, Antonio Cuneo, Luca Laurenti
Abstract
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study
Topics & Concepts
IbrutinibMedicineChronic lymphocytic leukemiaRetrospective cohort studyLeukemiaHepatitis B virusHematologyImmunologyHepatitis BInternal medicineVirusPediatricsChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentViral-associated cancers and disorders